Effect of the Simultaneous Working Length Control during Root Canal Preparation on Postoperative Pain

Hakan Arslan, PhD, DDS, Yahya Güven, DDS, Ertuğrul Karataş, PhD, DDS, and Ezgi Doğanay, PhD, DDS

Abstract

Aim: The aim of this study was to evaluate the effect of simultaneous length control during root canal preparation on postoperative pain compared with separate working length determination and root canal preparation. The design was a parallel-group, randomized, controlled trial with 2 arms. Methods: Forty-four molar teeth were randomly divided into 2 groups (n = 22), a control group (separate length determination and root canal preparation) and a simultaneous length control during root canal preparation group. The following variables were recorded: age; gender; tooth number; preoperative pain on the visual analog scale; pain level on days 1, 3, 5, and 7; and analgesic intake after the procedure and initial/final percussion pain. The data were analyzed with the χ^2 test, independent samples t test, and Mann-Whitney U test. Results: The simultaneous length control during root canal preparation group resulted in lower postoperative pain levels on day 1 than did the control group (P < .05). Despite 2 patients' intake of postoperative analgesics in the control group, no patient needed to use postoperative analgesics in the simultaneous length control during root canal preparation group (P > .05). **Conclusions:** Simultaneous length control during root canal preparation as a nonpharmacologic strategy for reducing postoperative pain is a beneficial technique for preventing postoperative pain. (*J Endod* 2017; ■:1–6)

Key Words

Endodontic treatment, Gold Reciproc motor, postoperative pain, reciprocation, root canal treatment, separate working length control, simultaneous working length control, working length determination Working length determination is one of the most important steps in endodontics. Failure to determine the working length can result in insufficient instrumentation of the root canal or in overinstrumentation of the root canal. This leads to the extrusion of materials such as irrigants and filling

Significance

Traditionally, the protection of the working length from deviations can be achieved manually by observing the stopper and coronal reference points. The Gold Reciproc motor allows for simultaneous length control during instrumentation with auto-stop function. According to the results of the present study, simultaneous length control during root canal preparation is a beneficial technique to prevent postoperative pain.

materials. The use of radiography and apex locators during root canal treatment are the most preferred techniques among clinicians for determining working length (1). According to a recent study, working length determination with an electronic apex locator is similar to the radiographic technique in terms of enabling the accurate determination of working length (2). Moreover, in another study, the effect of the determination of working length with an electronic apex locator and digital radiography on postoperative pain was evaluated, and no difference was found between the 2 groups (3).

The Gold Reciproc motor (VDW GmbH, Munich, Germany) is an electronic apex integrated endodontic motor that allows simultaneous length control during instrumentation. This motor was evaluated in a study and was found to be as reliable and accurate as conventional electronic apex locators (4). An interesting property of this motor is that when an instrument reaches the working length, the motor automatically stops the instrumentation. Thus, it can be concluded that automatically stopping instrumentation when the instrument reaches the working length would decrease postoperative pain compared with manually controlling the working length by using stoppers during instrumentation (separate length determination and root canal preparation).

Postoperative pain is a frequent problem in endodontics (5). Pharmacologic strategies for reducing postoperative pain include medication with acetaminophen (6), antihistamines (7), nonsteroidal anti-inflammatory drugs (8), steroidal anti-inflammatory drugs (9), salicylic acid (10), narcotic analgesics (11), a combination of 2 medications (12, 13), or using long-acting anesthesia (14). With regard to non-pharmacologic strategies for preventing postoperative pain, preoperative relaxation approaches and explanations for patients (15), glide path application (16), occlusal reduction (17), or using different kinematics during root canal treatment (18) have been used.

From the Department of Endodontics, Faculty of Dentistry, Ataturk University, Erzurum, Turkey.

Address requests for reprints to Dr Hakan Arslan, Department of Endodontics, Faculty of Dentistry, Ataturk University, Erzurum 35620, Turkey. E-mail address: dt_hakan82@hotmail.com

^{0099-2399/\$ -} see front matter

Copyright o 2017 American Association of Endodontists. http://dx.doi.org/10.1016/j.joen.2017.04.028

CONSORT Randomized Clinical Trial

ection/Topic	Item No	Checklist item	Reported on page No
itle and abstract	NU	Checklist Relli	on page No
tie and abstract	1a	Identification as a randomised trial in the title	Title page
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	1
troduction			
ackground and	2a	Scientific background and explanation of rationale	2-3
ojectives	2b	Specific objectives or hypotheses	3
ethods			
ial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	3
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	3
articipants	4a	Eligibility criteria for participants	3
	4b	Settings and locations where the data were collected	5
terventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were	4
utcomes	6a	actually administered Completely defined pre-specified primary and secondary outcome measures, including how and when they	5
	ou	were assessed	0
	6b	Any changes to trial outcomes after the trial commenced, with reasons	5
ample size	7a	How sample size was determined	5
	7b	When applicable, explanation of any interim analyses and stopping guidelines	-
andomisation:	80	Mathed used to generate the random allocation sequence	3
Sequence generation	8a 8b	Method used to generate the random allocation sequence Type of randomisation; details of any restriction (such as blocking and block size)	3
Allocation	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers),	3
concealment		describing any steps taken to conceal the sequence until interventions were assigned	
mechanism			
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to	3
in dia a	44-	interventions	4
inding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	4
			Page
	446	assessing outcomes) and how	Page
	11b 129	If relevant, description of the similarity of interventions	-
	11b 12a 12b	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes	Page
ONSORT 2010 checklist	12a	If relevant, description of the similarity of interventions	5
tatistical methods	12a	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes	5
tatistical methods tesults articipant flow (a iagram is strongly	12a 12b 13a	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	
tatistical methods esults articipant flow (a agram is strongly ecommended)	12a 12b 13a 13b	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons	- 5 5 5 5
tatistical methods esults articipant flow (a agram is strongly ecommended)	12a 12b 13a 13b 14a	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up	- 5 5 5 5 5
tatistical methods esults articipant flow (a iagram is strongly ecommended) ecruitment	12a 12b 13a 13b 14a 14b	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped	- 5 5 5 5 5 5 5 -
tatistical methods esults articipant flow (a iagram is strongly ecommended) ecruitment aseline data	12a 12b 13a 13b 14a	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up	- 5 5 5 5 5
tatistical methods results articipant flow (a iagram is strongly accommended) recruitment aseline data umbers analysed	12a 12b 13a 13b 14a 14b 15 16	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	
tatistical methods esults articipant flow (a iagram is strongly accommended) ecruitment aseline data lumbers analysed butcomes and	12a 12b 13a 13b 14a 14b 15	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each primary and secondary outcome, results for each group, and the estimated effect size and its	- 5 5 5 5 - 11
tatistical methods esults articipant flow (a iagram is strongly ecommended) ecruitment aseline data umbers analysed iutcomes and	12a 12b 13a 13b 14a 14b 15 16 17a	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	
tatistical methods results articipant flow (a iagram is strongly acommended) eccruitment aseline data lumbers analysed butcomes and stimation	12a 12b 13a 13b 14a 14b 15 16 17a 17b	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) For binary outcomes, presentation of both absolute and relative effect sizes is recommended	
tatistical methods results articipant flow (a iagram is strongly acommended) eccruitment aseline data lumbers analysed butcomes and stimation	12a 12b 13a 13b 14a 14b 15 16 17a	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	
tatistical methods articipant flow (a iagram is strongly accommended) tecruitment aseline data lumbers analysed butcomes and stimation ncillary analyses	12a 12b 13a 13b 14a 14b 15 16 17a 17b	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) For binary outcomes, presentation of both absolute and relative effect sizes is recommended Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing	
tatistical methods esults articipant flow (a iagram is strongly ecommended) ecruitment aseline data umbers analysed uucomes and stimation ncillary analyses arms	12a 12b 13a 13b 14a 14b 15 16 17a 17b 18	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) For binary outcomes, presentation of both absolute and relative effect sizes is recommended Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	
tatistical methods esults articipant flow (a iagram is strongly ecommended) ecruitment aseline data unbers analysed utcomes and stimation ncillary analyses arms iscussion imitations	12a 12b 13a 13b 14a 14b 15 16 17a 17b 18 19 20	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each group, and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) For binary outcomes, presentation of both absolute and relative effect sizes is recommended Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	
tatistical methods esults articipant flow (a lagram is strongly commended) ecruitment aseline data umbers analysed utcomes and stimation ncillary analyses arms iscussion mitations ieneralisability	12a 12b 13a 13b 14a 14b 15 16 17a 17b 18 19 20 21	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) For binary outcomes, presentation of both absolute and relative effect sizes is recommended Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses Generalisability (external validity, applicability) of the trial findings	
tatistical methods articipant flow (a iagram is strongly commended) tecruitment aseline data lumbers analysed vutcomes and stimation ncillary analyses larms iscussion mitations teneralisability tterpretation	12a 12b 13a 13b 14a 14b 15 16 17a 17b 18 19 20	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each group, and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) For binary outcomes, presentation of both absolute and relative effect sizes is recommended Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	
tatistical methods tarticipant flow (a iagram is strongly accommended) tecruitment taseline data lumbers analysed Dutcomes and stimation ancillary analyses larms Discussion imitations beneralisability interpretation Other information	12a 12b 13a 13b 14a 14b 15 16 17a 17b 18 19 20 21 22	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) For binary outcomes, presentation of both absolute and relative effect sizes is recommended Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses Generalisability (external validity, applicability) of the trial findings Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	- -
tatistical methods articipant flow (a iagram is strongly commended) tecruitment aseline data lumbers analysed vutcomes and stimation ncillary analyses larms iscussion mitations teneralisability tterpretation	12a 12b 13a 13b 14a 14b 15 16 17a 17b 18 19 20 21	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) For binary outcomes, presentation of both absolute and relative effect sizes is recommended Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses Generalisability (external validity, applicability) of the trial findings	
tatistical methods esults articipant flow (a agram is strongly ecruitment aseline data umbers analysed utcomes and stimation ncillary analyses arms iscussion imitations eneralisability iterpretation ther information egistration	12a 12b 13a 13b 14a 14b 15 16 17a 17b 18 19 20 21 22 23	If relevant, description of the similarity of interventions Statistical methods used to compare groups for primary and secondary outcomes Methods for additional analyses, such as subgroup analyses and adjusted analyses For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome For each group, losses and exclusions after randomisation, together with reasons Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped A table showing baseline demographic and clinical characteristics for each group For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) For binary outcomes, presentation of both absolute and relative effect sizes is recommended Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory All important harms or unintended effects in each group (tor specific guidance see CONSORT for harms) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses Generalisability (external validity, applicability) of the trial findings Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence Registration number and name of trial registry	- -

Figure 1. CONSORT checklist.

In this randomized, controlled clinical trial, Consolidated Standards of Reporting Trials (CONSORT) guidelines were followed (Fig. 1). The aim of the present study was to evaluate the effect of simultaneous length control during root canal preparation on postoperative pain compared with separate length determination and root canal preparation. The null hypothesis was that no differences in pain levels existed between the groups. Download English Version:

https://daneshyari.com/en/article/5640746

Download Persian Version:

https://daneshyari.com/article/5640746

Daneshyari.com